Vaccines pp 33-42 | Cite as

Use of Syntex Adjuvant Formulation to Enhance Immune Responses to Viral Antigens

Part of the NATO ASI Series book series (NSSA, volume 215)


There is both the need and the potential for the development of new vaccines and the improvement of existing vaccines. One aspect of this process is the development of better adjuvant formulations so that both humoral and cell-mediated immunity are enhanced. We have been interested in the adjuvant formulation area of vaccine development for some time, and believe that the Syntex Adjuvant Formulation (SAF) has a number of advantages that will make it very useful for both human and veterinary vaccines. SAF has been shown to increase both antibody synthesis and cell-mediated immunity to a variety of antigens in a number of species (Byars and Allison, 1987, Allison and Byars, 1988, Morgan et al, 1989). Cell-mediated responses have been measured by delayed hypersensitivity skin tests in vivo and by in vitro blastogenesis and/or interleukin-2 synthesis in response to antigen challenge. Animals have also been protected against live virus challenge, or against challenge with tumor cells, in situations where cell-mediated responses are a necessary component of protective immunity (Byars and McRoberts, 1986; Morgan et al, 1989; Campbell et al, 1990). SAF also increases efficacy of vaccines, compared to alum or saline control vaccines, thus allowing a reduction in either the amount of antigen per dose or in the number of doses required.


Muramyl Dipeptide Adjuvant Formulation Veterinary Vaccine Delay Hypersensitivity Skin Test Significant Antibody Titre 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Allison, A.C. and Byars, N.E., 1988, An adjuvant formulation for use with subunit and recombinant antigens, in: “Technological Advances in Vaccine Development”, L. Lasky, ed., Alan R. Liss, New York.Google Scholar
  2. Byars, N.E. and Allison, A.C., 1987, Adjuvant formulation for use in vaccines to elicit both cell mediated and humoral immunity, Vaccine, 5:223.PubMedCrossRefGoogle Scholar
  3. Byars, N.E., Allison, A.C., Harmon, M.W. and Kendal, A.B., 1990a, Enhancement of antibody responses to Influenza B virus hemagglutinin by use of a new adjuvant formulation, Vaccine, 8:49.PubMedCrossRefGoogle Scholar
  4. Byars, N.E. and McRoberts, M.J., 1986, Cell mediated responses to a feline leukemia virus vaccine, Abstracts of the Annual Meeting of the American Society for Microbiology, 99.Google Scholar
  5. Byars, N.E., Nakano, G., Welch, M., Lehman, D. and Allison, A.C., 1990b, Improvement of Hepatitis B vaccine by the use of a new adjuvant, Vaccine, in press.Google Scholar
  6. Campbell, M.J., Esserman, L., Byars, N.E., Allison, A.C. and Levy, R., 1990, Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity, J.Immunol., 145:1029.PubMedGoogle Scholar
  7. Kenney, J.S., Highes, B.W., Masada, M.P. and Allison, A.C., 1989, Influence of adjuvants on the quantity, affinity, 150 type and epitope specificity of murine antibodies, J. Immunol. Meth., 121:157.CrossRefGoogle Scholar
  8. Lidgate, D.M., Fu, R.C., Byars, N.E., Foster, L.C. and Fleitman, J.S., 1989, Formulation of vaccine adjuvant muramyldipeptides. 3. Processing optimization, characterization, and bioactivity of an emulsion vehicle, Pharm.Res., 6:748.PubMedCrossRefGoogle Scholar
  9. Milich, D.R. and Chisari, F.V., 1982, Genetic regulation of the immune response to hepatitis B surface antigen (HBsAg). 1. H-2 restriction of the murine humoral response to the a. and d determinants of HBsAg, J. Immunol., 129:320.PubMedGoogle Scholar
  10. Morgan, A.J., Allison, A.C., Finerty, S., Scullion, F.T., Byars, N.E. and Epstein, M.A., 1989, Validation of a first generation Epstein-Barr virus vaccine preparation suitable for human use, J.Med.Virol., 29:74.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  1. 1.Syntex ResearchPalo AltoUSA

Personalised recommendations